Keryx Biopharmaceuticals ( KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. This stock is trading up 15.8% at $1.68 in recent trading. Today's Range: $1.64-$1.76 52-Week Range: $1.28-$5.55 Volume: 4 million Three-Month Average Volume: 3.8 million Shares of KERX are skyrocketing today after Roth Capital Partners raised the stock to a buy rating from neutral. From a technical perspective, KERX is gapping up sharply here on above average volume. This move is quickly pushing the stock within range of triggering a near-term breakout trade. That trade will hit once KERX takes out some near-term overhead resistance at $1.75 to $1.97 with high-volume. Traders should now look for long-biased trades if KERX can sustain a move or close above those levels on volume that's near or above 3,791,530 shares. If we get that action soon, then KERX will a great chance of filling some of its massive gap-down from two months ago. Keryx was included on a list of 10 Best-Performing Stocks in a Three-Year Bull Market.